A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model

• DOI: 10.1371/journal.pone.0152913
• Publication Date: 2016-04-13T20:12:38Z
• Authors: Paul Walsh; Nicole Behrens; Francisco R. Carv...; Heather McEligot; Karan Agrawal; John W. Newman; Mark Anderson; Laurel J. Gershwin
• Keywords: Ibuprofen

Background Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and hospital admission in infants. An analogous disease occurs cattle costs US agriculture a billion dollars year. RSV causes much its morbidity indirectly via adverse effects host response to virus. accompanied by elevated prostaglandin E2 (PGE2) which followed neutrophil led inflammation lung. Ibuprofen prototypical non-steroidal anti-inflammatory drug that decreases PGE2 levels inhibiting cyclooxygenase. Hypotheses We hypothesized treatment with ibuprofen would decrease levels, modulate immune response, clinical illness, histopathological lung changes bovine model RSV. further viral replication be unaffected. Methods performed randomized placebo controlled trial 16 outbred Holstein calves we infected measured scores, cyclooxygenase, lipoxygenase endocannabinoid products plasma mediastinal lymph nodes interleukin (Il)-4, Il-13, Il-17 interferon-γ nodes. shedding was daily nasal Il-6, Il-8 every other day. The were necropsied on Day 10 post inoculation histology performed. Results One calf group required euthanasia 8 infection for respiratory distress. Clinical scores (p<0.01) weight gain (p = 0.08) seemed better group. decreased lipoxygenase, cytochrome P450 products, increased monoacylglycerols modulated as narrowed range observed IFN-γ gene expression Lung not different between groups, ibuprofen. Conclusions PGE2, improved outcomes. However histopathology affected increased.